

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists

Kanchan Dongre¹, Yasmin Schmid², Luana Nussbaum², Clemens Winterhalder³, Stefano Bassetti³, Andreas Holbro^{4,5}, Lukas Degen⁶, Anne B. Leuppi-Taegtmeyer^{1, 2 *}

1. *Department of Patient Safety, Medical Directorate, University Hospital Basel*
2. *Department of Clinical Pharmacology and Toxicology, University Hospital Basel and University of Basel, Basel, Switzerland*
3. *Division of Internal Medicine, University Hospital Basel and University of Basel, Basel, Switzerland*
4. *Blood Transfusion Centre, Swiss Red Cross, Basel, Switzerland*
5. *Department of Hematology, University Hospital Basel and University of Basel, Basel, Switzerland*
6. *Clarunis, University Center for Gastrointestinal and Liver Diseases, Basel, Switzerland*

* anne.leuppi-taegtmeyer@usb.ch

This file is a supplementary file to the article available at:

<https://doi.org/10.21542/gcsp.2022.21>

Supplemental Table 1: Classification of co-medication

Drugs causing pharmacodynamic interactions

Antiplatelet agents

Unfractionated heparin

Low-molecular-weight heparin

Non-steroidal anti-inflammatory drugs (NSAIDs)

Gingko biloba

Serotonin and dual serotonin and noradrenaline reuptake inhibitors

Drugs known to reduce the risk of GIB

Proton pump inhibitors

Antacids

Drugs known to increase the risk of GIB

NSAIDs

Glucocorticoids

Drugs causing pharmacokinetic interactions

Macrolide antibiotics

Highly active antiretroviral therapy (HAART)

Azoles

Antiepileptic drugs: phenobarbital, phenytoin, carbamazepine

Amiodarone

Verapamil

Diltiazem

Rifampicin

Hypericum

Drugs masking the clinical signs of GIB

Beta-blockers

Verapamil, diltiazem

